A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter…

Overview of attention for article published in American Journal of Hematology, July 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 12 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 23,221 followers.

A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. https://t.co/1ugDWF2mqT https://t.co/Ihw0Zv9JYN

13 Dec 2017

Reply Repost Favourite

RT @Myeloma_Doc: Biosimilar filgrastim + #Mozobil works well for stem cell mobilization in #myeloma & #lymphoma pts: https://t.co/VSlYrAFpP…

23 Jun 2017

Reply Repost Favourite

RT @Myeloma_Doc: Biosimilar filgrastim + #Mozobil works well for stem cell mobilization in #myeloma & #lymphoma pts: https://t.co/VSlYrAFpP…

20 Jun 2017

Reply Repost Favourite

Biosimilar filgrastim + #Mozobil works well for stem cell mobilization in #myeloma & #lymphoma pts: https://t.co/VSlYrAFpPq. https://t.co/YTOtn6t9hn

18 Jun 2017

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.